SB-408124 is a drug which is a non-peptide antagonist selective for the orexin receptor subtype OX1, with around 70x selectivity for OX1 over OX2 receptors...
3 KB (158 words) - 21:33, 22 January 2024
antagonist SB-334867 – first non-peptide selective OX1 antagonist – has been shown to produce sedative and anorectic effects in animals SB-408124 – selective...
19 KB (1,978 words) - 11:32, 1 May 2024
Fazamorexant (YZJ-1139) Filorexant GSK-649868 (SB-649868) Lemborexant Nivasorexant (ACT-539313) RTIOX-276 SB-334867 SB-408124 Suvorexant TCS-1102 Tebideutorexant...
21 KB (1,687 words) - 04:21, 27 January 2024
example, blocking the orexin-1 receptor with the selective orexin antagonist SB-334,867 reduced nicotine self-administration in rats and that smokers who...
54 KB (6,129 words) - 20:20, 27 June 2024
Fazamorexant (YZJ-1139) Filorexant GSK-649868 (SB-649868) Lemborexant Nivasorexant (ACT-539313) RTIOX-276 SB-334867 SB-408124 Suvorexant TCS-1102 Tebideutorexant...
48 KB (4,078 words) - 11:27, 24 July 2024
Fazamorexant (YZJ-1139) Filorexant GSK-649868 (SB-649868) Lemborexant Nivasorexant (ACT-539313) RTIOX-276 SB-334867 SB-408124 Suvorexant TCS-1102 Tebideutorexant...
5 KB (301 words) - 11:39, 13 January 2024
doi:10.1002/ana.26641. PMC 10330114. PMID 36897120. S2CID 257444346. Schipper SB, Van Veen MM, Elders PJ, van Straten A, Van Der Werf YD, Knutson KL, et al...
94 KB (8,956 words) - 03:07, 14 August 2024
RTIOX-276 – selective OX1 receptor antagonist SB-334867 – selective OX1 receptor antagonist SB-408124 – selective OX1 receptor antagonist Seltorexant...
13 KB (1,234 words) - 02:29, 15 August 2024
Fazamorexant (YZJ-1139) Filorexant GSK-649868 (SB-649868) Lemborexant Nivasorexant (ACT-539313) RTIOX-276 SB-334867 SB-408124 Suvorexant TCS-1102 Tebideutorexant...
8 KB (532 words) - 07:00, 2 November 2023
SB-334867 is an orexin antagonist. It was the first non-peptide antagonist developed that is selective for the orexin receptor subtype OX1, with around...
10 KB (996 words) - 21:32, 22 January 2024